Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine☆
References (50)
- et al.
Treatment of idiopathic orthostatic hypotension (Shy-Drager syndrome) with indomethacin
Lancet
(1978) - et al.
Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure
- et al.
Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes
Neurol Clin
(1992) Multiple system atrophy: clinical aspects, pathophysiology and treatment
Orthostatic hypotension
Med Clin North Am
(1989)- et al.
Management of chronic orthostatic hypotension
Am J Med
(1986) - et al.
The clinical spectrum of autonomic dysfunction
Am J Med
(1981) - et al.
Idiopathic onthostatic hypotension: a study of its natural history in 57 neurologically affected patients
Arch Neurol
(1970) - et al.
Midodrine: a new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome
Mayo Clin Proc
(1981) - et al.
Treatment of postural hypotension: a review
Drugs
(1990)
Mineralocorticoid-induced hypotension in patients with orthostatic hypotension
N Engl J Med
Pharmacological responses and biochemical changes in progressive autonomic failure
Treatment of chronic orthostatic hypotension with ergotamine
Circulation
Treatment of orthostatic hypotension with dihydroergotamine
BMJ
Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy
Clin Pharmacol Ther
Idiopathic postural hypotension: physiological observations and reports of a new mode of therapy
J Clin Invest
Effect of indomethacin inhibition of prostaglandin synthesis on blood pressure and plasma norepinephrine levels in patients with orthostatic hypotension
Neurology
Treatment of severe orthostatic hypotension by metoclopropamide
Ann Intern Med
Clonidine raises blood pressure in idiopathic orthostatic hypotension
Am J Med
Atrial tachypacing in the treatment of a patient with primary orthostatic hypotension
N Engl J Med
Orthostatic hypotension: II. Clinical diagnosis, testing, and treatment
Arch Intern Med
Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins
Eur J Clin Pharmacol
Effects of a-adrenoceptor agonists on cardiac output and blood pressure in spinally anesthetized ganglion-blocked dogs
Arch Int Pharmacodyn Ther
Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059
Arzneimittelforschung
Pharmacodynamics of midodrine, an antihypotensive agent
Clin Pharmacol Ther
Cited by (342)
Disease-modifying vs symptomatic treatments: Splitting over lumping
2023, Handbook of Clinical NeurologyMidodrine use in critically ill patients: a narrative review
2022, Critical Care and ResuscitationCardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
2022, Clinical TherapeuticsNew approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies
2022, NeuropharmacologyCitation Excerpt :No ransomised, double-blind, placebo-controlled trials have evaluated the efficacy of midodrine, a short-acting α1-adrenoreceptor agonist, on OH in a homogenous cohort of patients with PD. However, a series of high-quality trials have confirmed its efficacy in heterogenous groups of patients with n-OH, including subjects with PD (Jankovic et al., 1993; Low et al., 1997; Smith et al., 2016). The long-acting synthetic mineralocorticoid, fludrocortisone, is commonly used in clinical practice for treating OH in PD, based on outcomes from two small double-blind RCTs with a cross-over design comparing the efficacy of fludrocortisone with domperidone or pyridostigmine bromide, respectively, in patients with PD and OH (Schoffer et al., 2007; Schreglmann et al., 2017).
Midodrine
2022, Primer on the Autonomic Nervous System, Fourth EditionPrinciples and Practice of Movement Disorders
2021, Principles and Practice of Movement Disorders
- ☆
This study was supported by a grant-in-aid from Roberts Pharmaceutical Corporation, Eatontown, New Jersey. This work was presented as an abstract at the 43rd Annual Meeting of the American Academy of Neurology, Boston, Massachusetts, April 21–27, 1991.